Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors: Pair-matched case-control study

Davor Eterović, Marina Titlić, Viktor Čulić, Renata Zadro, Dragan Primorac

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease. In these studies the controls were derived from the general population, with fewer clinical risk factors, which might have produced biased results. The factor V Leiden and prothrombin G20210A mutations were examined by polymerase chain reaction technique in 120 ischemic stroke patients and 120 controls younger than 65 years of age. Each patient had his own control, tightly matched in clinical risk factors. The prevalences of factor V Leiden and prothrombin G20210A mutations in patients were 8.3% (P = 0.02) and 7.5% (P = 0.04), respectively, and 2.5% for controls for both mutations. All carriers were single heterozygotes. In patients, but not in controls, the carriers of either mutation were mostly women and with fewer clinical risk factors for arterial ischemic events. In particular, considering both mutations as a single coagulation deficit, their presence increased the likelihood of ischemic stroke (odds ratio [OR] = 3.6; 95% confidence interval [CI] 1.4-9.3), especially among women (OR = 4.6; 95% CI: 1.2-17.8), normotensive persons (OR = 9.2; 95% CI: 1.1-17.8) and those having normal cholesterol (OR = 5.9; 95% CI: 1.6-21.2) and triglyceride serum concentrations (OR = 4.3; 95% CI: 1.5-12.8). In the studied sample of adult North Mediterranean population younger than 65 years the prevalences of factor V Leiden and prothrombin G20210A mutations were greater in patients with ischemic stroke than in matched controls. Unlike in studies with unmatched controls, we observed an apparently negative interaction of these mutations with clinical risk factors.

Original languageEnglish (US)
Pages (from-to)188-193
Number of pages6
JournalClinical and Applied Thrombosis/Hemostasis
Volume13
Issue number2
DOIs
StatePublished - Apr 1 2007

Fingerprint

Case-Control Studies
Stroke
Mutation
Prothrombin
Odds Ratio
Confidence Intervals
factor V Leiden
Heterozygote
Population
Triglycerides
Cholesterol
Polymerase Chain Reaction
Serum

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Eterović, Davor ; Titlić, Marina ; Čulić, Viktor ; Zadro, Renata ; Primorac, Dragan. / Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors : Pair-matched case-control study. In: Clinical and Applied Thrombosis/Hemostasis. 2007 ; Vol. 13, No. 2. pp. 188-193.
@article{e35c0392f7e64cfe829afa79a5dc158f,
title = "Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors: Pair-matched case-control study",
abstract = "It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease. In these studies the controls were derived from the general population, with fewer clinical risk factors, which might have produced biased results. The factor V Leiden and prothrombin G20210A mutations were examined by polymerase chain reaction technique in 120 ischemic stroke patients and 120 controls younger than 65 years of age. Each patient had his own control, tightly matched in clinical risk factors. The prevalences of factor V Leiden and prothrombin G20210A mutations in patients were 8.3{\%} (P = 0.02) and 7.5{\%} (P = 0.04), respectively, and 2.5{\%} for controls for both mutations. All carriers were single heterozygotes. In patients, but not in controls, the carriers of either mutation were mostly women and with fewer clinical risk factors for arterial ischemic events. In particular, considering both mutations as a single coagulation deficit, their presence increased the likelihood of ischemic stroke (odds ratio [OR] = 3.6; 95{\%} confidence interval [CI] 1.4-9.3), especially among women (OR = 4.6; 95{\%} CI: 1.2-17.8), normotensive persons (OR = 9.2; 95{\%} CI: 1.1-17.8) and those having normal cholesterol (OR = 5.9; 95{\%} CI: 1.6-21.2) and triglyceride serum concentrations (OR = 4.3; 95{\%} CI: 1.5-12.8). In the studied sample of adult North Mediterranean population younger than 65 years the prevalences of factor V Leiden and prothrombin G20210A mutations were greater in patients with ischemic stroke than in matched controls. Unlike in studies with unmatched controls, we observed an apparently negative interaction of these mutations with clinical risk factors.",
author = "Davor Eterović and Marina Titlić and Viktor Čulić and Renata Zadro and Dragan Primorac",
year = "2007",
month = "4",
day = "1",
doi = "10.1177/1076029606298999",
language = "English (US)",
volume = "13",
pages = "188--193",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "2",

}

Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors : Pair-matched case-control study. / Eterović, Davor; Titlić, Marina; Čulić, Viktor; Zadro, Renata; Primorac, Dragan.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 13, No. 2, 01.04.2007, p. 188-193.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors

T2 - Pair-matched case-control study

AU - Eterović, Davor

AU - Titlić, Marina

AU - Čulić, Viktor

AU - Zadro, Renata

AU - Primorac, Dragan

PY - 2007/4/1

Y1 - 2007/4/1

N2 - It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease. In these studies the controls were derived from the general population, with fewer clinical risk factors, which might have produced biased results. The factor V Leiden and prothrombin G20210A mutations were examined by polymerase chain reaction technique in 120 ischemic stroke patients and 120 controls younger than 65 years of age. Each patient had his own control, tightly matched in clinical risk factors. The prevalences of factor V Leiden and prothrombin G20210A mutations in patients were 8.3% (P = 0.02) and 7.5% (P = 0.04), respectively, and 2.5% for controls for both mutations. All carriers were single heterozygotes. In patients, but not in controls, the carriers of either mutation were mostly women and with fewer clinical risk factors for arterial ischemic events. In particular, considering both mutations as a single coagulation deficit, their presence increased the likelihood of ischemic stroke (odds ratio [OR] = 3.6; 95% confidence interval [CI] 1.4-9.3), especially among women (OR = 4.6; 95% CI: 1.2-17.8), normotensive persons (OR = 9.2; 95% CI: 1.1-17.8) and those having normal cholesterol (OR = 5.9; 95% CI: 1.6-21.2) and triglyceride serum concentrations (OR = 4.3; 95% CI: 1.5-12.8). In the studied sample of adult North Mediterranean population younger than 65 years the prevalences of factor V Leiden and prothrombin G20210A mutations were greater in patients with ischemic stroke than in matched controls. Unlike in studies with unmatched controls, we observed an apparently negative interaction of these mutations with clinical risk factors.

AB - It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease. In these studies the controls were derived from the general population, with fewer clinical risk factors, which might have produced biased results. The factor V Leiden and prothrombin G20210A mutations were examined by polymerase chain reaction technique in 120 ischemic stroke patients and 120 controls younger than 65 years of age. Each patient had his own control, tightly matched in clinical risk factors. The prevalences of factor V Leiden and prothrombin G20210A mutations in patients were 8.3% (P = 0.02) and 7.5% (P = 0.04), respectively, and 2.5% for controls for both mutations. All carriers were single heterozygotes. In patients, but not in controls, the carriers of either mutation were mostly women and with fewer clinical risk factors for arterial ischemic events. In particular, considering both mutations as a single coagulation deficit, their presence increased the likelihood of ischemic stroke (odds ratio [OR] = 3.6; 95% confidence interval [CI] 1.4-9.3), especially among women (OR = 4.6; 95% CI: 1.2-17.8), normotensive persons (OR = 9.2; 95% CI: 1.1-17.8) and those having normal cholesterol (OR = 5.9; 95% CI: 1.6-21.2) and triglyceride serum concentrations (OR = 4.3; 95% CI: 1.5-12.8). In the studied sample of adult North Mediterranean population younger than 65 years the prevalences of factor V Leiden and prothrombin G20210A mutations were greater in patients with ischemic stroke than in matched controls. Unlike in studies with unmatched controls, we observed an apparently negative interaction of these mutations with clinical risk factors.

UR - http://www.scopus.com/inward/record.url?scp=34047263414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047263414&partnerID=8YFLogxK

U2 - 10.1177/1076029606298999

DO - 10.1177/1076029606298999

M3 - Article

C2 - 17456629

AN - SCOPUS:34047263414

VL - 13

SP - 188

EP - 193

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 2

ER -